Update on NMOSD & MOGAD programme
The two-day Update on NMOSD and MOGAD meeting offers an in-depth exploration of the latest advancements in these fields.
On Day 1, the programme will focus on recent progress in research, diagnosis, clinical management, and emerging therapies for NMOSD and MOGAD, with expert-led sessions providing a comprehensive update.
Day 2 will include a key-note lecture on epidemiology and features free communications, poster sessions, and industry symposia. These will provide opportunities to share innovative research, discuss findings, and showcase the latest developments from the pharmaceutical industry. The meeting will conclude with an overview of the situation in Latin America, providing valuable regional insights.
Participants can attend the meeting either onsite or online.
The programme follows the Brazil/São Paulo Time zone: (UTC/GMT -03:00)
| Hour Location |
Title | Location |
|---|---|---|
|
8:30-9:00 |
Opening Remarks Dr. Hans-Peter Hartung Dr. Jefferson Becker Dr. Jacqueline Palace |
|
|
9:00-11:00 |
Session 1: Diagnosis, Differential Diagnosis and Prognosis Dr. Hans-Peter Hartung Dr. Alfredo Damasceno |
|
| 9:00-9:30 |
Clinical and Prognostic Features of NMOSD Dr. Ricardo Alonso |
|
| 9:30-10:00 |
Clinical and Prognostic Features of MOGAD Dr. Douglas Kazutoshi Sato |
|
| 10:00-10:30 |
Imaging Dr. Friedemann Paul |
|
| 10:30-11:00 |
Evoked Potentials & OCT Dr. Letizia Leocani |
|
|
11:00-11:30 |
Coffee Break |
|
|
11:30-12:30 |
Session 2: Diagnosis and Monitoring Dr. Kazuo Fujihara Dr. Jefferson Becker |
|
| 11:30-12:00 |
Antibody Assays and Use in Diagnosis and Monitoring Dr. Jacqueline Palace |
|
| 12:00-12:30 |
The New MS Diagnostic Criteria: Implications on Differential Diagnosis with NMOSD and MOGAD Dr. Hans-Peter Hartung |
|
|
12:30-13:30 |
Industry Symposium AMGEN - NMOSD Treatment Landscape, Global to Local: Real Life Experiences in Germany and Brazil Dr. Orhan Aktas Dr. Douglas Kazutoshi Sato |
|
|
13:45-15:45 |
Session 3: Treatments and Symptoms Dr. Marco Aurélio Lana Peixoto Dr. Claudia Carcamo |
|
| 13:45-14:15 |
Acute Relapse Treatments Dr. Fu-Dong Shi |
|
| 14:15-14:45 |
Hidden Symptoms / Symptomatic Treatments Dr. Jefferson Becker |
|
| 14:45-15:15 |
Conventional Chronic Treatments Dr. Kazuo Fujihara |
|
| 15:15-15:45 |
New and Future Treatments Dr. Romain Marignier |
|
|
15:45-16:15 |
Coffee Break |
|
|
16:15-17:45 |
Session 4: Treatment in Practice Dr. Romain Marignier Dr. Samira Apóstolos |
|
| 16:15-16:45 |
General Discussion - all speakers : How Should We Use the Conventional and the New Treatments in Clinical Parctice? |
|
| 16:45-17:15 |
Case-based Discussions: NMOSD Dr. Kazuo Fujihara Dr. Friedemann Paul Dr. Katharina Messias Dr. Denis Bichuetti |
|
| 17:15-17:45 |
Case-based Discussions: MOGAD Dr. Jacqueline Palace Dr. Milena Pitombeira Dr. Douglas Sato Kazutoshi Dr. Katharina Messias |
|
|
17:45-18:15 |
Guthy Jackson Lecture Dr. Maria Fernanda Mendes Dr. Claudia Carcamo |
|
| 17:45-18:15 |
Restoring Tolerance Dr. Michael Yeaman |
|
|
19:00-22:00 |
Welcome Dinner - Sponsored by The Sumaira Foundation |
| Hour Location |
Title | Location |
|---|---|---|
|
8:30-9:00 |
Key Note Lecture Dr. Osvaldo Nascimento Dr. Giordani Passos |
|
| 8:30-9:00 |
Epidemiology of NMOSD & MOGAD Dr. Marco Aurélio Lana Peixoto |
|
|
9:00-10:30 |
Session 5 : Oral Communications Dr. Henry Sato Dr. Livia Almeida Dutra |
|
| 9:00-9:15 |
Multiparametric brain MRI and cognitive impairment in NMOSD Dr. Mateus Bonaventura |
|
| 9:15-9:30 |
4-Octyl itaconate inhibits inflammation via the NLRP3 pathway in NMOSD Dr. Rui Liu |
|
| 9:30-9:45 |
Neutrophils in MOGAD/NMOSD: effectors of neural damage and differentiators vs MS Dr. David Leppert |
|
| 9:45-10:00 |
Anti-MOG Antibody Associated Disease in Chile: A Longitudinal Study Dr. Carolina Pelayo |
|
| 10:00-10:15 |
The Unmet Needs in the 2022 Optic Neuritis Classification Dr. Marco Aurélio Lana Peixoto |
|
| 10:15-10:30 |
Brain Characteristics in Patients with MOGAD by 7.0 T MRI Dr. Zhihui Qi |
|
|
10:30-11:00 |
Coffee Break |
|
|
11:00-12:00 Exhibition Hall |
Poster Visit |
Exhibition Hall |
|
12:00-13:00 |
Industry Symposium ALEXION- ASTRA ZENECA - Lunch Box Offered |
|
|
13:00-14:00 |
Session 6: Oral Communications - Basic Studies Dr. Vinicius Boldrini Dr. Lorna Galleguillos |
|
| 13:00-13:15 |
Type-I IFN signaling augments autoreactive T cells and aggregates NMOSD Dr. Tian-Xiang Zhang |
|
| 13:15-13:30 |
AQP4-specific T cells determine lesion localization in the CNS in a model of NMOSD Dr. Ali Maisam Afzali |
|
| 13:30-13:45 |
Impact of AQP4-IgG antibodies on astrocyte in NMOSD: a biochemical approach Dr. Ana Paula Bornes Da Silva |
|
| 13:45-14:00 |
M23 isoform is superior to M1 for detecting AQP4-IgG seroreversion during NMOSD Dr. Vinicius Boldrini |
|
|
14:00-15:00 |
Industry Symposium ROCHE: Satralizumab in NMOSD - Real World Experience Dr. Douglas Kazutoshi Sato Dr. Kazuo Fujihara |
|
|
15:00-15:30 |
Industry Lecture AMGEN: Advancing NMOSD Care: Patient Profiles and Insights on Inebilizumab in Brazil Dr. Mateus Boaventura de Oliveira |
|
|
15:30-16:00 |
Coffee Break |
|
|
16:00-17:30 |
Session 7 : NMOSD and MOGAD in LATAM Dr. Bruna Klein da Costa Dr. Ana Claudia Piccolo |
|
| 16:00-16:30 |
NMOSD in LATAM Dr. Edgar Carnero Contentti |
|
| 16:30-17:00 |
Treatment Guidelines for NMOSD in LATAM Dr. Alfredo Damasceno |
|
| 17:00-17:30 |
MOGAD in LATAM Dr. Ethel Ciampi |
|
|
17:30-18:00 |
Closing Ceremony Dr. Hans-Peter Hartung Dr. Jefferson Becker Dr. Jacqueline Palace |